drugset / Trial / NCT05809934
A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 given by subcutaneous injection in adult participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis and who are carriers of the PNPLA3 148M Risk Allele
Timeline
- Start
- 2023-03-15
- Primary completion
- 2025-07-14
- Completion
- 2025-09-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD2693 | Antisense oligonucleotide | — | Subcutaneous |